Pharma Industry Presentaion

of 20

  • date post

    09-Apr-2018
  • Category

    Documents

  • view

    221
  • download

    0

Embed Size (px)

Transcript of Pharma Industry Presentaion

  • 8/7/2019 Pharma Industry Presentaion

    1/20

  • 8/7/2019 Pharma Industry Presentaion

    2/20

    The pharmaceutical industry develops,

    produces, and markets drugs licensed for

    use as medications. Pharmaceutical

    companies can deal in generic and/or

    brand medications.

    Pharmaceutical Industry - Indian Perspective 2

  • 8/7/2019 Pharma Industry Presentaion

    3/20

    Pharmaceutical Industry -

    Worldwide 2008:

    Year for addressing structural and operationalissues

    Determiningwhere future growth will be found

    Positioning the industry for reform and otherchanges

    Beginning of2009, Global PharmaceuticalMarket Major state of flux

    Pharmaceutical usage continued to expand,albeit more slowly than in previous years

    Generics continued to pick up market shareglobally

    3Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    4/20

    Pharma Industry Growth Rates

    Worldwide

    US Pharma Market (comprising 47% of the

    global pharma market share) grew by 1%

    Canadian Pharma Market grew by 7%

    Five major European Pharma Markets grew

    by 2%

    Indian Pharma Market year enggrowth

    rate expected around 12% in 2009.Domestic Retail Sales grew by 18.3% in June

    09 and by 8.9% in July 09

    Pharmaceutical Industry - Indian Perspective 4

  • 8/7/2019 Pharma Industry Presentaion

    5/20

    Pharmaceutical Industry - India

    5Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    6/20

    Source: Socio Economic Review 2007-08

    6Pharmaceutical Industry - Indian Perspective

    Chemical & Pharma 22.9% of the

    Indian Industries

  • 8/7/2019 Pharma Industry Presentaion

    7/20

    7Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    8/20

    Composition of the Pharma

    Industry in Gujarat

    8Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    9/20

    Key Facts & Figures

    9Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    10/20

    Top 5 Global Pharma

    Companies

    Top 5 Indian Pharma

    Companies

    I. CiplaII. Ranbaxy

    III. GSK

    IV. Piramal Health Care

    V. Zydus Cadila

    (Sun as on Feb. 09)

    Top Performing Drugs

    I. Lipitor (Pfizer)

    II. Plavix (Bristol)

    III. Meyer Squibb (Sanofi

    Aventis)

    IV. Nexium (Astra Zeneca)

    V. Seretide/Advair (GSK)

    VI. Enbrel (Wyeth)

    IN INDIA:

    Rank 1: Voveran

    (Novartis)

    Pharmaceutical Industry - Indian Perspective 10

    I. PfizerII. Glaxo Smith Kline (GSK)

    III. Astra Zeneca

    IV. Novartis

    V. Sanofi Aventis

    Source: IMS Data 2008

  • 8/7/2019 Pharma Industry Presentaion

    11/20

    Market Share of Pharma

    Companies in India

    Cipla, 5.3

    Ranbaxy, 5

    GSK, 4.3

    PiramalHealthcare

    , 3.9

    Zydus

    Cadila, 3.6Cipla

    Ranbaxy

    GSK

    Piramal Healthcare

    Zydus Cadila

    Pharmaceutical Industry - Indian Perspective 11

    These Top 5 Companies govern 22% of the

    Domestic Pharma Market

  • 8/7/2019 Pharma Industry Presentaion

    12/20

    Key Exports Notifications Year 2009

    Indias export volume to US hampered(down by 40%) Competition fromChina, Israel & Korea

    Reasons for Export Downfall : Fluctuating Dollar (liquidity problems)

    Ban on Ranbaxy

    Competition from other Asian countries Aggressive pricing by Chinese exporters

    Cancellation of Orders

    12Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    13/20

    Indian Advantage

    40% to 50% savings in raw materials

    8

    5% to90

    % manpower cost savings

    FDA-approved plants can be constructedin India at 30% to 50% lower costs

    Higher utilisation of equipment due toimproved processes

    13Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    14/20

    Indias Regulatory framework

    14Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    15/20

    Contract Research &

    manufacturing Emerging Sectors

    Indian drugdiscovery anddevelopment outsourcing market is

    projected to grow at a rate of 50 % in 2009

    Indian pharmaceutical manufacturing outsourcing market is valued

    at US$ 1.1 billion and the segment is growing at thrice the global

    market rate

    Indias share of the outsourcing market to increase from 2.8% in

    2007 to 5.5% in 2010

    APIs /intermediate outsourcing is more prevalent in India than

    formulation outsourcing; around64 % of total outsourcing is in thearea of APIs/intermediates. APIs and intermediate demand is likely

    to be in the range of US$ 600 million to US$ 700 million by 2010

    By 2010, the demand for contract manufacturing of formulations to

    be around US$ 210 million to US$ 300 million

    15Pharmaceutical Industry - Indian Perspective

  • 8/7/2019 Pharma Industry Presentaion

    16/20

    R & D Efforts

    Pharmaceutical Industry - Indian Perspective 16

  • 8/7/2019 Pharma Industry Presentaion

    17/20

    Future of Pharmaceutical Industry

    MNCs in India to control 8-9% in

    domestic pharma market worth $8

    billion by 2015

    Indian Pharma Market expected to triple

    to $20 billion by 2015 Moving towards

    Worlds Top 10 Markets

    Focus of Indian Companies shifting from

    the US

    Pharmaceutical Industry - Indian Perspective 17

  • 8/7/2019 Pharma Industry Presentaion

    18/20

  • 8/7/2019 Pharma Industry Presentaion

    19/20

    Porters Five Forces Model

    Barrier to entry: High (Pharmaceuticals)!Cost of R&D and patent limitations

    Industry Competition: High! Advantagesgained by first mover advantage(patents)

    Suppliers: Supplier power is low!

    Buyers: Buyer power is low! Substitutes: Low(with patents), Medium(after patent expiry)

    Pharmaceutical Industry - Indian Perspective 19

  • 8/7/2019 Pharma Industry Presentaion

    20/20

    SWOT

    Pharmaceutical Industry - Indian Perspective 20